About Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.

The company was founded in 2015 by Max Krummel, Ph.D., a professor at University of California, San Francisco School of Medicine (UCSF), who has been making significant strides in immuno-oncology since the mid-1990s. Dr. Krummel is the co-inventor of YERVOY® (ipilimumab), the first checkpoint inhibitor, which was approved in 2011 to treat melanoma. Pionyr has exclusively licensed technology from UCSF based on Dr. Krummel’s work.

Pionyr’s investors include Gilead, New Enterprise Associates, OrbiMed, SV Health Investors, Sofinnova Investments, Vida Ventures, Osage University Partners, Mission Bay Capital, and Trinitas Ventures.

Pionyr’s Path


Pionyr Founded


$1.3M Series A Funding


$8M Series A-1 OrbiMed, SV, Osage, Mission Bay


4 TME-Targeted mABs in Process


Located at MBC BioLabs


$69M Series B NEA, Sofinnova, Vida, Trinitas + Prior Investors


New Labs at Genesis Towers


Gilead Investment


PY314 and PY159 into P1



Pionyr/Lonza Partnership

Pionyr's Third Program



PY314 Ph1b Expansion Cohorts



Steven P. James photo

Steven P. James / CEO



Janet Awaya / Senior Director, Finance

Kevin Baker PhD photo

Kevin Baker, PhD / Senior Vice President and Chief Development Officer

Tony Brew photo

Tony Brew / Senior Director, Information Technology

Marc Chamberlain photo

Marc Chamberlain, MD / Executive Medical Director


Davide Edghill / Senior Director, Data Management

Larry Garrido photo

Larry Garrido / Senior Director, Facilities Operations

Evan Greger photo

Evan Greger, MBA, MSc / Senior Vice President and Chief Technical Officer

Lynnae Jackson photo

Lynnae Jackson, MBA / Vice President, Clinical Operations

Alicia Levey, PhD photo

Alicia Levey, PhD / President and Chief Operating Officer

Yunfeng Li photo

Yunfeng Li, PhD / Senior Director, Biostatistics

Linda Liang Photo

Linda Liang, PhD / Vice President, Protein Sciences

Isabel Luther photo

Isabel Luther / VP, Clinical Operations

Monte Montgomery photo

Monte Montgomery / Executive Vice President and Chief Financial Officer

Steven P. James photo

Kristen Pierce, PhD / VP, Translational Medicine

Leonard Reyno photo

Leonard Reyno, MD / President, R&D and Chief Medical Officer

Lisa Stemmerich photo

Lisa Stemmerich, MBA / Senior Vice President and Chief Human Resources Officer

Board of Directors

J.C. Lopez  / NEA

Rishi Gupta, JD / OrbiMed

Steven P. James / CEO, Pionyr Immunotherapeutics

Regina Salvat, PhD / Sofinnova

Mike Ross, PhD / SV Health Investors


gilead logo

nea logo

orbimed logo

sofinnova logo

sv health investors logo

vida ventures logo

osage logo

mission bay capital logo

trinitas capital logo


ProBiogen logo

celonic logo

Lonza logo

celonic logo